New cancer drug nearly doubles pancreatic cancer survival
Pancreatic cancer is one of the deadliest cancers. A new drug has nearly doubled median survival compared to standard treatment in a clinical trial.
The US Food and Drug Administration has approved daraxonrasib for the treatment of advanced pancreatic cancer. The drug, sold under the brand name Rasonque, was developed by the biopharmaceutical company Revolution Medicines. The study underpinning the approval showed that patients who received daraxonrasib as a second-line treatment achieved a median overall survival of 13.2 months, compared to 6.7 months for patients offered standard chemotherapy.
A genetic cause as the target
Daraxonrasib targets a genetic cause of pancreatic cancer. It is the first drug to work this way against this specific tumour type. The precise biological target is described in the source as a genetic mutation that frequently occurs in pancreatic cancer, though further molecular details are not elaborated in the summary.
Pancreatic cancer is typically detected late, which has historically kept survival rates low. Existing second-line treatments such as standard chemotherapy offered limited benefit. A near-doubling of median survival is a notable result in this disease area, though median figures say nothing about individual patient outcomes.
What this means for longevity research
Cancer is one of the leading causes of premature death and a major barrier to a longer healthy lifespan. Targeted therapies (drugs that attack specific genetic abnormalities in tumours) are a growing part of oncology. Whether daraxonrasib is relevant for other tumour types or for prevention is not addressed by the available information at this time.
The drug is now approved in the United States. Availability in other countries is not yet known.
Want to research this yourself?
Search for example:
- targeted pancreatic cancer therapy
- second-line oncology treatment
- genetic mutation tumour targeting